Konstantinos Efthymiopoulos

Janssen Pharmaceuticals, Inc. develops and markets prescription drugs in various therapeutic areas, including attention deficit hyperactivity disorder, pain management, acid reflux and infectious diseases, women’s health, and mental health (bipolar I disorder and schizophrenia); and neurologic, including Alzheimer’s disease, epilepsy, and migraine prevention and treatment. Its products include Axert, Darzalezx, Invokamet XR, Invokana, Remicade, Reopro, and Risperdal Consta. The company was founded by Paul Janssen in 1953 and is headquartered in Titusville, NJ.

Corob Oy supplies color tinting systems. It offers complete tinting solutions: CPSCOLOR TM colorants (liquid pigments), COROB TM dispensing and mixing/shaking equipment, software, color marketing tools, customer support and service. The firm serves paint manufacturers, retail chains, leather and plastics producers. The company was founded in 2000 and is headquartered in Pori, Finland.

Polpharma Biologics Utrecht BV operates as a biopharmaceutical research and development company. It specializes in the development of monoclonal antibodies generation, cell line, upstream process, downstream process, analytical, and bioassay development services. The company is headquartered in Utrecht, the Netherlands.

Aravis AG (Aravis) is an independent venture capital firm, founded in 2001 by Jean-Philippe Tripet and headquartered in Muttenz, Switzerland.

Biogeneration Management is a venture capital firm, a subsidiary of BioGeneration Holding BV and was founded in 2006. Biogeneration management is headquartered in Naarden.

S*BIO is a privately-held biotech company focused on the research and clinical development of novel targeted small molecule drugs for the treatment of cancer with leading programs around histone deacetylases (HDAC) and kinases. S*BIO's lead candidate, SB939, entered the clinic in 2007. SB1518, S*BIO's potent and orally-active JAK2 inhibitor, entered the clinic in 2008 and has received orphan drug designation from the U.S. FDA. S*BIO has entered into a development collaboration, and option & license agreement with Onyx Pharmaceuticals, Inc. to develop and commercialize SB1518 and its other novel JAK2 inhibitor, SB1578. S*BIO's SB1317, a novel multikinase inhibitor, is in pre-clinical development and under a worldwide exclusive license with Tragara Pharmaceuticals, Inc. for its development and commercialization. In line with its vision to be a leading fully-integrated oncology-focused biotech company in Asia Pacific, S*BIO has established a state-of-the-art R&D infrastructure, complemented by a strong clinical development team. S*BIO has strong links with a network of medical oncologists in Asia Pacific and its investors include EDB Investments' biomedical sciences subsidiary Bio*One Capital, Aravis Ventures, Novartis Bioventures and other international funds. In 2009, S*BIO received the BioSpectrum Editor's Choice, Emerging BioScience Company of Singapore Award.

Stichting Mibiton promotes research, development, and entrepreneurship in the life sciences sector. The foundation is focused on biomedical sciences, chemistry, food, agricultural, and environmental technology. Stichting Mibiton was founded in 1994, formally called as Stichting Publieke Private Samenwerking Versterking van de Materiële Infrastructuur BioTechnologisch Onderzoek in Nederland and is based in The Hague, The Netherlands.

Evolva SA is a Swiss-headquartered, international pharmaceutical biotech company focused on the discovery and development of drugs based on its distinctive and proprietary genetic chemistry platform. The company was founded in Switzerland in 2004 based on US/Danish technology. Evolva is headquartered in Allschwil/Basel with operations in Denmark, India and the USA. The Company has raised CHF 38.2 million of equity to date and employs 75 persons of whom 30 are based in Allschwil. The firm's strategy and business approach is based on five pillars that offer a sustainable development path for creating a successful company, which include Building a balanced portfolio. Evolva focuses on orally available small molecules in the belief that they are more convenient for patients and more cost-effective both from manufacture and administration points of view for the society, focus on differentiated pharmaceutical products with major benefits. Focusing on cardiovascular/renal and infectious diseases. Together they cause more than 50% of all deaths worldwide. Most of the top 20 pharmaceutical companies are active in both sectors, and all are active in one of the two sectors - hence widening Evolva's opportunities to partner. Building technology platform as the source of this differentiation. Evolva finds different structures with different properties from those found by the 99% of the industry that focuses on synthetic chemistry or proteins. Openness to unusual markets. The biotech business model has changed. As well as the established markets new opportunities arise in emerging countries such as India and China, and in adjacent sectors such as treatments against potential bio-terrorist and bio-warfare agents and the production of pharmaceutical and industrial chemical intermediates. Cost-effective implementation. Evolva places different functions around the globe according to where local conditions best suit. This approach both reduces Evolva's cost base and increases access to revenues, partners and talent. Evolva sees revenues and partners as important because they provide additional flexibility, resources and talent. Also, they provide important opportunities to better understand, and better meet, the needs of current and future customers.

Bird Rock Bio, Inc. develops protein therapeutics. It focuses on the discovery and development of novel antibodies with upsized potential that represent to antibody therapeutics. The company was founded by Richard J. Ulevitch, Phyllis Ellen Whiteley and Katherine S. Bowdish in 2007 and is headquartered in La Jolla, CA.

Aravis Venture II LP invests in biotechnological start-ups with growth potential.

Targovax Oy focuses on the development and commercialization of targeted cancer immunotherapy. It is a biotechnology company with novel immunotherapy platform that is based on engineered oncolytic viruses armed with potent immune-stimulating transgenes. The firm's products induce a tailored response by the immune system directed at each patient’s unique cancer cells. The company was founded by Pekka Ilmari Simula and Antti Vuolanto in 2009 and is headquartered in Helsinki, Finland.

Cristal Delivery BV develops and manufactures nanomedicines for therapeutic drug optimization. It offers pipeline, oncology, and inflammation programs. The company was founded by Joost J. M. Holthuis and Cristianne Rijcken in April 2011 and is headquartered in Maastricht, the Netherlands.

Quadia SA (Quadia) is an independent investment firm founded in 2010. The firm is headquartered in Switzerland.

Confo Therapeutics NV develops pharmaceutical products. It is a drug discovery company building internal drug discovery programs on GPCRs addressing unmet medical need. The company was founded by Jan Steyaert and Toon Laeremans in June 2015 and is headquartered in Brussels, Belgium.

Merck Ventures BV (Merck Ventures) is a venture capital arm of Merck KGaA founded in 2009. The firm is headquartered in Amsterdam, the Netherlands.

Escalier Biosciences BV develops biological products. The company is headquartered in Nijmegen, the Netherlands.

Scenic Biotech BV is using genomics to develop innovative therapies for patients affected by severe diseases. The company was founded by Thijn Brummelkamp and Sebastian Nijman and is headquartered in Amsterdam, Netherlands.

Viopas Venture Consulting GmbH (Viopas Venture Consulting) is a venture capital firm founded in 2016 by Simon Jules Nebel. The firm is headquartered in Zürich, Switzerland.

DyCare is a Spanish company that specializes in digital rehabilitation. The company is based in Barcelona, Spain. The company creates ultra-personalized exercises and monitor patients in a simple and effective way. The company's technology allows patients to perform therapeutic exercises using only their mobile phone or tablet camera, assisted by artificial intelligence. The company was founded by Silvia Raga and Ricardo Jauregui, who have been the CEOs since incorporation.

Genase Therapeutics BV develops therapeutic products to treat solid tumors. The company is based in Oss, Netherlands.

TigaTx BV is a Dutch company that provides research and development in the field of health nutrition. The company is based in Utrecht, the Netherlands. The company was founded in 2020 by Jeanette Leusen.

Dualyx NV is a biotech company based in Ghent, Belgium that focuses on developing novel Treg-based therapies for patients with difficult-to-treat autoimmune diseases. The CEO of the company is Wouter Verhoeven, and it is located in Zwijnaarde, Belgium. Dualyx has developed a pipeline of highly promising immune modulating programs, including DT-001, an antibody agonist program targeting the TNF receptor 2 (TNFR2), which is currently in IND-enabling studies. The Belgian company aims to create next-generation biologic drugs for autoimmunity therapies with novel mechanisms of action, lower toxicity, and improved patient outcomes than traditional therapeutics. The company was founded in 2020 by Luc van Rompaey in collaboration with Wurzburg University, Argenx, VIB, Ghent University, and KU Leuven.

TigaTx, Inc. is a biotechnology company that focuses on developing first-in-class, engineered IGA as neutrophil engagers to fight cancer. The company is based in Boston, MA. TigaTx is backed by excellent investors and has an accomplished scientific advisory board. It was founded by Jeanette Leusen and the CEO is Anne Altmeyer.